explore -WSS

explore

author：Wikipedia 2025-09-03 07:50:32 - browse：76

Stock illustration of computer and medication — Adobe

Half a year after selling its assets at bankruptcy auction, Pear Therapeutics’ most significant digital treatments will find a new life as part of PursueCare, which provides online addiction care and mental health counseling.

PursueCare today announced it had raised a $20 million Series B round and that it had acquired Pear’s portfolio of apps that treat people with addiction problems. PursueCare’s CEO Nick Mercadante told STAT the company hopes to develop the market for the treatments where Pear could not, by taking advantage of its access to patients and insurers.

“My view of digital therapeutics is that those point solutions really need a horse to draw the carriage,” he said. “You need a willing and capable service provider that says we’re going to make this a big part of real world care and… then show the health plans how it can save them money in the real world without extra thinking.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Ancient Greek ideas underpin modern concepts of pregnancy

knowledge

WSS

Microsoft's Peter Lee: Generative AI could help doctors be more human

AstraZeneca loses challenge to Medicare drug price negotiation

RaDonda Vaught to speak at CommonSpirit event on patient safety

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Congress gives doctors Medicare pay bump

For AI in health care standards, federal regulators join with industry group

Wikipedia

explore

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

FogPharma raises $145 million in rare Series E round

How one medical school became remarkably diverse

Longer MASH drug regimen improved liver, Akero study finds

How to save PrEP access — and even expand it

Scientists unlock the key to scar

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Hepatitis C has a cure — but many Americans still lack access to it

Change Healthcare: What is it, why does its cyberattack matter?

leisure time

$1 billion proposal to grow Boston, Massachusetts biotech

Medicare drug price negotiation continues, as pharma counteroffers

The public health thinking behind the CDC’s new Covid guidance

Longer MASH drug regimen improved liver, Akero study finds

Change Healthcare cyberattack outage could last weeks

The untold story of TV’s first prescription drug ad

focus

leisure time

knowledge

explore